Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma:

Patients:

Inclusion Criteria:

* Benign meningioma (grade I), or atypical meningioma (grade II)
* Histologic proven of benign meningioma, atypical meningioma or unequivocal radiological diagnosis of skull base meningioma if biopsy is recused.
* Indication of irradiation validated by a multidisciplinary meeting
* Age \>20 years and \<65 years
* Expected overall survival \>10 years
* Adjuvant or exclusive irradiation is allowed.
* Signed informed consent form
* WHO Performance status equal to 0 or 1
* Patient affiliated to the French social health insurance
* Patient whose neuropsychological abilities allow to follow the requirements of the protocol

Exclusion Criteria:

* Patient with mutation in a known predisposition gene (NF-2, SMARCE-1).
* Cerebrovascular pathology, presence of other tumors of the nervous system, congenital malformations of the nervous system, multiple sclerosis, Parkinson's disease, organic psychosis (other than dementia), or schizophrenia.
* Other localization than skull base meningioma
* Histology/radiological features rather different than grade I-II meningioma
* Histologic proven grade III meningioma
* Uncontrolled epilepsy
* Contraindication to MRI
* Patient with a history of brain irradiation.
* Patient with a history of cancer in the last five years (excluding skin baso-cellular carcinoma)
* Pregnant/breastfeeding woman
* Any geographical conditions, social and associated psychopathology that may compromise the patient's ability to participate in the study
* Participation in a therapeutic trial evaluating a radiotherapy schedule or a new drug or combination for less than 30 days
* Patient deprived of freedom or under guardianship
* Hypersensibility to Gadolinium

Participants free of brain disease or cancer history:

Inclusion Criteria:

* Subject without any history of neurological disease (cerebral stroke, epilepsy, Intra cranial Neurosurgery procedure, meningioma, pituitary adenoma, Parkinson disease,Dementia…) or absence of personality disorders and progressive psychiatric pathology
* Age \>20 years and \<65 years
* Signed informed consent form
* WHO Performance status equal to 0 or 1
* Subject affiliated to the French social health insurance
* Subject whose neuropsychological abilities allow to follow the requirements of the protocol
* No major cognitive disorder that may compromise the realization of cognitive evaluations, defined as a MoCA score in accordance with the threshold depending on age and educational level according to the GRECOGVASC normative data

Non-inclusion criteria

* Cerebrovascular pathology, presence of other tumors of the nervous system, congenital malformations of the nervous system, multiple sclerosis, Parkinson's disease, organic psychosis (other than dementia), or schizophrenia
* History of epilepsy with antiepileptic drug
* Subject with a history of brain irradiation
* Subject with a history of cancer in the last five years (Excluding skin baso-cellular carcinoma)
* Pregnant/breastfeeding woman
* Any geographical conditions, social and associated psychopathology that may compromise the subject's ability to participate in the study
* Participation in a therapeutic trial - Subject deprived of freedom or under guardianship